Smith & Nephew Lists €500m Long-Dated Notes on London Stock Exchange
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
An update from Smith & Nephew Snats ( (SNN) ) is now available.
On 3 June 2026, Smith & Nephew plc announced that EUR 500 million of 4.250% notes due 3 June 2038 have been admitted to trading on the Main Market of the London Stock Exchange. The notes were issued under the company’s US$5 billion Euro Medium Term Note programme, marking a significant long-term financing move that deepens its presence in European capital markets and provides additional funding flexibility for its medical technology operations.
The securities carry an aggregate nominal amount of EUR 500 million and are supported by a prospectus dated 17 March 2026 and a supplemental prospectus dated 15 May 2026. This admission to trading underscores Smith & Nephew’s ability to tap public debt markets for sizable, long-dated funding, which may help support its investment plans, balance sheet management, and broader strategic initiatives in the healthcare sector.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company that develops and markets orthopaedic implants, sports medicine and ear, nose and throat treatments, and advanced wound management products. It serves hospitals and healthcare providers globally, with its shares listed on the London Stock Exchange and debt issued under an established Euro Medium Term Note programme.
Average Trading Volume: 1,055,301
Technical Sentiment Signal: Hold
Current Market Cap: $12.47B
See more insights into SNN stock on TipRanks’ Stock Analysis page.
